Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 44
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
2.
Clin Calcium ; 25(11): 1681-8, 2015 Nov.
Artículo en Japonés | MEDLINE | ID: mdl-26503874

RESUMEN

Gastrectomy is undergone mainly in patients with gastric cancer. Bone diseases(osteoporosis and osteomalacia)caused by gastractomy are associated with weight loss, calcium and vitamin D inadequancy, and malnutrition. Most patients after gastrectomy have multile risk factors of bone diseases and subsequently are at a higher risk for fractures. In particular, sex hormone deficiency and aging enhance the risk for fractures. The management of bone diseases caused by gastraectomy include adequet intake of calcium, vitamin D and protein, sunlight exposure, and regular weight-bearing exercise, as well as non-smoking and avoiding excess alcohol drinking. The patients at a high risk for fractures shoud be treated with bisphosphonates.


Asunto(s)
Enfermedades Óseas/prevención & control , Fracturas Óseas/prevención & control , Gastrectomía/efectos adversos , Densidad Ósea , Enfermedades Óseas/complicaciones , Enfermedades Óseas/epidemiología , Suplementos Dietéticos , Terapia por Ejercicio , Humanos
4.
Chin J Physiol ; 57(5): 231-7, 2014 Oct 31.
Artículo en Inglés | MEDLINE | ID: mdl-25241982

RESUMEN

High-dose glucocorticoids reduce cortical bone gain in rats. The aim of the present study was to examine the effect of the intermittent administration of human parathyroid hormone (1-34) (hPTH[1-34]) on cortical bone in rats treated with high-dose prednisolone (PSL). Twenty-five female Sprague-Dawley rats (6 weeks old) were randomized into the following three groups: a vehicle administration (control) group, a PSL (10 mg/kg s.c., 5 times a week) administration group, and a PSL + hPTH(1-34) (30 µg/kg s.c., 3 times a week) administration group. After 8 weeks of treatment, the bone mineral density (BMD) of the femoral diaphysis was determined using peripheral quantitative computed tomography, and a static bone histomorphometric analysis was performed on the tibial diaphysis. PSL administration induced a decrease in the BMD of the femoral diaphysis, compared with the control group, as well as decreases in the total tissue area, cortical area, percent cortical area, and periosteal perimeter and increases in the marrow area, percent marrow area, and endocortical perimeter of the tibial diaphysis, compared with the control group. The intermittent administration of hPTH(1-34) to PSL-treated rats attenuated PSL-related changes in the BMD of the femoral diaphysis and the percent cortical area, marrow area, percent marrow area, and endocortical perimeter of the tibial diaphysis. The findings of the present study suggest that the intermittent administration of hPTH(1-34) improves cortical BMD, acts on the endocortical bone surface, and improves cortical bone geometry, in rats treated with highdose PSL.


Asunto(s)
Diáfisis/efectos de los fármacos , Fémur/efectos de los fármacos , Prednisolona/farmacología , Teriparatido/farmacología , Tibia/efectos de los fármacos , Animales , Fenómenos Biomecánicos/efectos de los fármacos , Densidad Ósea/efectos de los fármacos , Conservadores de la Densidad Ósea/farmacología , Diáfisis/fisiología , Relación Dosis-Respuesta a Droga , Femenino , Fémur/fisiología , Glucocorticoides/farmacología , Humanos , Distribución Aleatoria , Ratas Sprague-Dawley , Tibia/fisiología
5.
Asia Pac J Clin Nutr ; 23(2): 256-62, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24901095

RESUMEN

Serum undercarboxylated osteocalcin (ucOC) is an index of vitamin K nutritional status in treatment-naive postmenopausal osteoporotic women. The purpose of the present study was to reveal the association between vitamin K nutritional status and serum ucOC concentrations in postmenopausal osteoporotic women taking bisphosphonates. Eighty-six postmenopausal women with osteoporosis (age range: 47-90 years) initiated bisphosphonate treatment. Vitamin K nutritional status was evaluated using a simple vitamin K-intake questionnaire and serum ucOC concentrations were measured after 6 months of treatment. The patients were divided into two groups according to the simple vitamin K-intake questionnaire score: a low vitamin K-intake (score <40) group (n=67) and a normal vitamin K-intake (score >=40) group (n=19). There were no significant differences between the groups in baseline parameters including age, height, body weight, body mass index, serum alkaline phosphatase (ALP), urinary cross-linked N-terminal telopeptides of type I collagen (NTX), and changes in serum ALP and urinary NTX concentrations during the 6-month treatment period. However, the mean serum ucOC concentration after 6 months of treatment was significantly higher in the low vitamin K-intake group (2.79 ng/mL) than in the normal vitamin K-intake group (2.20 ng/mL). These results suggest that 78% of postmenopausal osteoporotic women treated with bisphosphonates may have vitamin K deficiency as indicated by low vitamin K-intake and high serum ucOC concentrations, despite having a similar reduction in bone turnover to women who have normal vitamin K-intake.


Asunto(s)
Difosfonatos/uso terapéutico , Estado Nutricional/fisiología , Osteocalcina/sangre , Osteoporosis Posmenopáusica/sangre , Deficiencia de Vitamina K/tratamiento farmacológico , Vitamina K/sangre , Anciano , Anciano de 80 o más Años , Conservadores de la Densidad Ósea/sangre , Conservadores de la Densidad Ósea/uso terapéutico , Difosfonatos/sangre , Estudios de Seguimiento , Humanos , Japón , Persona de Mediana Edad , Osteoporosis Posmenopáusica/tratamiento farmacológico , Encuestas y Cuestionarios , Resultado del Tratamiento , Vitamina K/administración & dosificación , Deficiencia de Vitamina K/sangre
6.
Ther Clin Risk Manag ; 9: 171-6, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23637537

RESUMEN

PURPOSE: Vitamin D supplementation is suggested to reduce the risk of falls in older institutionalized or ambulatory individuals by 20%. The present study was undertaken to address the reduced risk, by vitamin D supplementation, of falls and hip fractures in patients with vascular Parkinsonism (VP) and Parkinson's disease (PD). PATIENTS AND METHODS: In the open-label-study, 94 elderly patients with VP and 92 age-matched patients with PD were followed for 2 years. All patients received 1200 IU ergocalciferol daily. The number of falls per person and incidence of hip fractures were compared between the two groups. RESULTS: At baseline, serum 25-hydroxyvitamin D (25-OHD) levels were in the deficient range (<25 nmol/L) in all patients, and vitamin D treatment enhanced serum 25-OHD and 1,25-dihydroxyvitamin D levels in both groups. Improved muscle strength of lower extremities was observed in both groups. There was significant difference between the two groups in the number of falls per subject during the 2 years (1.9 ± 0.5 in the PD group and 0.8 ± 0.4 in the VP group, P < 0.001). Hip fractures occurred in seven of 88 in the PD group and one in 90 of the VP group during the 2-year study period (P = 0.035). CONCLUSION: It is suggested that vitamin D decreases falls and hip fractures in VP by increasing muscle strength but not in PD.

7.
World J Orthop ; 3(9): 137-41, 2012 Sep 18.
Artículo en Inglés | MEDLINE | ID: mdl-23173109

RESUMEN

Hypovitaminosis D and K due to malnutrition or sunlight deprivation, increased bone resorption due to immobilization, low bone mineral density (BMD) and an increased risk of falls may contribute to an increased risk of hip fractures in patients with Parkinson's disease. The purpose of the present study was to clarify the efficacy of interventions intended to prevent hip fractures in elderly patients with Parkinson's disease. PubMed was used to search the literature for randomized controlled trials (RCTs) regarding Parkinson's disease and hip fractures. The inclusion criteria were 50 or more subjects per group and a study period of 1 year or longer. Five RCTs were identified and the relative risk and 95% confidence interval were calculated for individual RCTs. Sunlight exposure increased serum hydroxyvitamin D [25(OH)D] concentration, improved motor function, decreased bone resorption and increased BMD. Alendronate or risedronate with vitamin D supplementation increased serum 25(OH)D concentration, strongly decreased bone resorption and increased BMD. Menatetrenone (vitamin K(2)) decreased serum undercarboxylated osteocalcin concentration, decreased bone resorption and increased BMD. Sunlight exposure (men and women), menatetrenone (women), alendronate and risedronate with vitamin D supplementation (women) significantly reduced the incidence of hip fractures. The respective RRs (95% confidence intervals) according to the intention-to-treat analysis were 0.27 (0.08, 0.96), 0.13 (0.02, 0.97), 0.29 (0.10, 0.85) and 0.20 (0.06, 0.68). Interventions, including sunlight exposure, menatetrenone and oral bisphosphonates with vitamin D supplementation, have a protective effect against hip fractures elderly patients with Parkinson's disease.

8.
Clin Calcium ; 21(9): 1323-8, 2011 Sep.
Artículo en Japonés | MEDLINE | ID: mdl-21881194

RESUMEN

Mechanical load which comes mainly from muscle force as well as gravitational force associated with body weight plays an important role in increasing bone mass and bone strength. The greater is mechanical load to the bone, the larger are the increases in bone mass and bone strength. In particular, jumping exercise produces a large amount of mechanical forces loaded to the bone through muscle force. Jumping exercise together with calcium supplementation during the pre- and peri-pubertal periods is reported to be effective in stimulating bone growth and thereby increasing bone mineral content. In girls, interventions must be initiated during the pre-menarcheal period to effectively maximize peak bone mass.


Asunto(s)
Densidad Ósea/fisiología , Desarrollo Óseo/fisiología , Ejercicio Físico/fisiología , Soporte de Peso/fisiología , Animales , Peso Corporal/fisiología , Calcio/metabolismo , Niño , Ensayos Clínicos como Asunto , Femenino , Humanos , Masculino , Menarquia/fisiología , Ratas , Estrés Mecánico
9.
Kurume Med J ; 57(4): 117-24, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21778673

RESUMEN

A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. We previously found that vitamin K deficiency and low 25-hydroxyvitamin D (25-OHD) with compensatory hyperparathyroidism cause reduced bone mineral density (BMD) in female patients with AD. This may modifiable by intervention with menatetrenone (vitamin K2) and risedronate sodium; we address the possibility that treatment with menatetrenone, risedronate and calcium may reduce the incidence of nonvertebral fractures in elderly patients with AD. A total of 231 elderly patients with AD were randomly assigned to daily treatment with 45 mg of menatetrenone or a placebo combined with once weekly risedronate sodium, and followed up for 12 months. At baseline, patients of both groups showed high undercarboxylated osteocalcin (ucOC) and low 25-OHD insufficiency with compensatory hyperparathyroidism. During the study period, BMD in the treatment group increased by 5.7% and increased by 2.1% in the control group. Nonvertebral fractures occurred in 15 patients (10 hip fractures) in the control group and 5 patients (2 hip fractures) in the treatment group. The relative risk in the treatment group compared with the control group was 0.31 (95% confidence interval, 0.12-0.81). Elderly AD patients with hypovitaminosis K and D are at increased risk for hip fracture. The study medications were well tolerated with relatively few adverse events and effective in reducing the risk of a fracture in elderly patients with AD.


Asunto(s)
Enfermedad de Alzheimer/complicaciones , Ácido Etidrónico/análogos & derivados , Fracturas de Cadera/prevención & control , Osteoporosis/complicaciones , Vitamina D/análogos & derivados , Vitamina K 2/análogos & derivados , Anciano , Anciano de 80 o más Años , Densidad Ósea , Conservadores de la Densidad Ósea/farmacología , Ácido Etidrónico/uso terapéutico , Femenino , Hemostáticos/farmacología , Humanos , Hiperparatiroidismo/patología , Masculino , Osteoporosis/prevención & control , Ácido Risedrónico , Vitamina D/sangre , Vitamina K/metabolismo , Vitamina K 2/uso terapéutico
10.
Nutr Rev ; 69(3): 162-7, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21348880

RESUMEN

Type 2 diabetic patients are at high risk of bone fractures even if their bone mineral density is normal or high. This is likely explained by poor bone quality and extraskeletal factors. The present review was conducted to provide an overview of the currently available preclinical and clinical evidence on the effect of vitamin K(2) on bone quality in persons with type 2 diabetes. Vitamin K(2) stimulates γ-carboxylation of osteocalcin and can increase bone formation through steroid and xenobiotic receptors. Clinical studies of type 2 diabetic patients have shown detrimental collagen cross-links in bone; low serum insulin-like growth factor-I and osteocalcin concentration are associated with an increased risk of fractures. A therapeutic strategy for preventing fractures in type 2 diabetic patients remains to be established. One recent preclinical study showed that vitamin K(2) administration in a type 2 diabetic rat model had the following skeletal benefits: increased serum osteocalcin, improved collagen cross-link profiles, and increased bone strength. These new findings suggesting a possible beneficial effect of vitamin K(2) supplementation on bone quality in type 2 diabetes warrant further investigation.


Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Densidad Ósea/efectos de los fármacos , Huesos/efectos de los fármacos , Huesos/fisiología , Diabetes Mellitus Tipo 2/complicaciones , Vitamina K 2/uso terapéutico , Densidad Ósea/fisiología , Conservadores de la Densidad Ósea/administración & dosificación , Ensayos Clínicos como Asunto , Diabetes Mellitus Tipo 2/metabolismo , Humanos , Osteoporosis/prevención & control , Vitamina K 2/administración & dosificación
11.
Am J Phys Med Rehabil ; 90(4): 281-6, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21273899

RESUMEN

OBJECTIVE: To determine the pathogenesis of the stooped posture in Parkinson disease (PD), we prospectively studied fractures in a cohort of patients with Parkinson disease for 5 yrs. DESIGN: At baseline, we recorded the dietary intake of vitamin D and serum concentrations of parathyroid hormone and 25-hydroxyvitamin D. Bone mineral density and lateral thoracic and lumbar spine radiographs were obtained at baseline and every year for 5 yrs. RESULTS: During the 5-yr study period, stooped posture developed in 34 patients; the rest of the 58 patients did not show stooped posture. At baseline, mean serum 25-hydroxyvitamin D and parathyroid hormone levels were 10.9 ng/ml and 73.1 pg/ml, respectively, in the stooped group and 18.6 ng/ml and 56.4 pg/ml, respectively, in the nonstooped group. Bone mineral density in the stooped group was significantly lower than in the nonstooped group. Dietary intake of vitamin D in the stooped group was significantly lower than in the nonstooped group. During the study period, 19 (22%) patients in the nonstooped group developed new vertebral fracture, compared with 23 (100%) patients in the stooped group. The mean ± SD percentage changes in bone mineral density were -6.5 ± 0.6 in the stooped group and -3.8 ± 0.8 in the nonstooped group. Mean serum levels of 25-hydroxyvitamin D after 5 yrs were 7.0 ng/ml in the stooped group and 14.1 ng/ml in the nonstooped group. CONCLUSIONS: Stooped posture in Parkinson disease may be caused by vertebral fractures resulting from vitamin D deficiency with compensatory hyperparathyroidism. Vitamin D supplementation may reduce stooped posture in patients with Parkinson disease.


Asunto(s)
Vértebras Lumbares/lesiones , Enfermedad de Parkinson/patología , Postura , Fracturas de la Columna Vertebral/etiología , Vértebras Torácicas/lesiones , Deficiencia de Vitamina D/complicaciones , Anciano , Densidad Ósea , Estudios de Cohortes , Femenino , Humanos , Masculino , Persona de Mediana Edad , Hormona Paratiroidea/metabolismo , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/metabolismo , Fracturas de la Columna Vertebral/metabolismo , Fracturas de la Columna Vertebral/patología , Vitamina D/análogos & derivados , Vitamina D/metabolismo , Deficiencia de Vitamina D/metabolismo , Deficiencia de Vitamina D/patología
12.
Aging Clin Exp Res ; 22(2): 116-22, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19920410

RESUMEN

BACKGROUND AND AIMS: Lumbar spinal stenosis (LSS), osteoarthritis (OA) of the knee, and osteoporosis are major locomotive diseases in the elderly population. The aim of this study was to examine the effectiveness of exercise in these three diseases. METHODS: We reviewed the relevant literature, i.e., systematic reviews and meta-analyses searched with PubMed. RESULTS: There is not sufficient evidence to draw conclusions regarding the effectiveness of exercise for LSS. However, muscle strengthening and aerobic exercises are effective in reducing pain and improving physical function in patients with mild to moderate OA of the knee. On the other hand, aerobics, weight bearing and resistance exercises are effective in increasing the bone mineral density of the spine in postmenopausal women, and walking is effective for the hips. Muscle strengthening, balance training and traditional Chinese Tai Chi reduce the risk of falls in the elderly. CONCLUSIONS: Based on a review of the literature, appropriate exercises should be emphasized for elderly patients, especially for those with mild to moderate OA of the knee or osteoporosis.


Asunto(s)
Terapia por Ejercicio/métodos , Articulación de la Rodilla/fisiopatología , Osteoartritis/terapia , Osteoporosis/terapia , Estenosis Espinal/terapia , Accidentes por Caídas/prevención & control , Femenino , Humanos , Vértebras Lumbares/fisiopatología , Persona de Mediana Edad , Osteoporosis/prevención & control , Posmenopausia
13.
Aging Clin Exp Res ; 21(4-5): 277-81, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19959915

RESUMEN

BACKGROUND AND AIMS: Hypovitaminosis D and K due to malnutrition or sunlight deprivation, compensatory hyperparathyroidism, increased bone resorption, low bone mineral density (BMD), and an increased risk of falls may contribute to an increased risk of hip fractures in patients with Alzheimer's disease. The purpose of the present study was to clarify the efficacy of interventions against hip fractures in patients with Alzheimer's disease. METHODS: With respect to randomized controlled trials (RCTs) regarding Alzheimer's disease and hip fractures, the literature was searched with PubMed. RESULTS: Three RCTs were identified, and the relative risk (RR) and 95% confidence interval (CI) were calculated for individual RCTs. Exposure to sunlight with calcium supplementation, menatetrenone (vitamin K2) plus calcium and vitamin D supplementation, and risedronate plus calcium and vitamin D supplementation improved hypovitaminosis D and hyperparathyroidism, contributing to a reduction in bone resorption. Risedronate itself strongly decreased bone resorption. Menatetrenone also decreased the serum level of undercarboxylated osteocalcin. The three interventions increased metacarpal BMD and reduced the incidence of hip fractures. The respective RRs (95% CI) were 0.22 (0.049-0.999), 0.13 (0.031-0.554), and 0.26 (0.100- 0.690). CONCLUSIONS: The present study clarified the efficacy of three interventions, including exposure to sunlight, menatetrenone, and risedronate with calcium and/or vitamin D supplementation against hip fractures in patients with Alzheimer's disease.


Asunto(s)
Enfermedad de Alzheimer/complicaciones , Enfermedad de Alzheimer/tratamiento farmacológico , Enfermedad de Alzheimer/radioterapia , Conservadores de la Densidad Ósea/uso terapéutico , Densidad Ósea/efectos de los fármacos , Ácido Etidrónico/análogos & derivados , Fracturas de Cadera/prevención & control , Luz Solar , Anciano , Calcio/uso terapéutico , Trastornos del Conocimiento/etiología , Suplementos Dietéticos , Ácido Etidrónico/uso terapéutico , Femenino , Hemostáticos/uso terapéutico , Fracturas de Cadera/epidemiología , Humanos , Masculino , Ensayos Clínicos Controlados Aleatorios como Asunto , Ácido Risedrónico , Vitamina D/uso terapéutico , Vitamina K 2/análogos & derivados , Vitamina K 2/uso terapéutico
14.
Clin Calcium ; 19(12): 1805-14, 2009 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-19949272

RESUMEN

The objective of the present review of the literature was to evaluate the effect of vitamin K supplementation on the skeleton of postmenopausal women. PubMed was used to search the reliable literature for randomized controlled trials (RCTs) by using the inclusion criteria: >or= approximately 50 subjects per group and study period of >or= 2 years. The results of 7 RCTs that met the inclusion criteria showed that vitamin K (K(1) and K(2)) supplementation reduced serum undercarboxylated osteocalcin levels regardless of dose, but that it had inconsistent effects on serum total osteocalcin levels and no effect on bone resorption. Despite the lack of a significant change or the occurrence of only a modest increase in bone mineral density, high-dose vitamin K supplementation improved indices of bone strength in the femoral neck and reduced the incidence of clinical fractures. Furthermore, a post hoc analysis in a large RCT in Japan showed that high-dose vitamin K(2) supplementation decreased the subsequent incidence of vertebral fractures in osteoporotic postmenopausal women with a history of at least 5 vertebral fractures. The review of the reliable literature showed the effect of high-dose vitamin K supplementation on the skeleton of postmenopausal women mediated by mechanisms other than bone mineral density and bone turnover.


Asunto(s)
Fracturas Espontáneas/prevención & control , Osteoporosis Posmenopáusica/prevención & control , Vitamina K/uso terapéutico , Densidad Ósea/efectos de los fármacos , Femenino , Fracturas Espontáneas/etiología , Humanos , Metaanálisis como Asunto , Osteocalcina/sangre , Osteoporosis Posmenopáusica/etiología , Ensayos Clínicos Controlados Aleatorios como Asunto , Fracturas de la Columna Vertebral/prevención & control , Vitamina K/administración & dosificación
15.
Nutr Res ; 29(4): 221-8, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19410972

RESUMEN

Although systematic review and meta-analysis of randomized controlled trials (RCTs) have concluded that vitamin K is effective in preventing fractures, the effect of vitamin K on the skeleton remains a matter of controversy. The objective of the present review of the literature was to evaluate the effect of vitamin K supplementation on the skeleton of postmenopausal women. PubMed was used to search the reliable literature for RCTs by using the search terms "vitamin K(1) or vitamin K(2)," "bone," and "postmenopausal women" and the following inclusion criteria: approximately 50 or more subjects per group and study period of 2 years or longer. Seven RCTs met the inclusion criteria. The results of these RCTs showed that vitamin K(1) and vitamin K(2) supplementation reduced serum undercarboxylated osteocalcin levels regardless of dose but that it had inconsistent effects on serum total osteocalcin levels and no effect on bone resorption. Despite the lack of a significant change or the occurrence of only a modest increase in bone mineral density, high-dose vitamin K(1) and vitamin K(2) supplementation improved indices of bone strength in the femoral neck and reduced the incidence of clinical fractures. The review of the reliable literature confirmed the effect of vitamin K(1) and vitamin K(2) supplementation on the skeleton of postmenopausal women mediated by mechanisms other than bone mineral density and bone turnover.


Asunto(s)
Conservadores de la Densidad Ósea/uso terapéutico , Huesos/efectos de los fármacos , Suplementos Dietéticos , Fracturas Óseas/prevención & control , Vitamina K/uso terapéutico , Densidad Ósea/efectos de los fármacos , Conservadores de la Densidad Ósea/farmacología , Relación Dosis-Respuesta a Droga , Femenino , Cuello Femoral/efectos de los fármacos , Humanos , Osteocalcina/sangre , Posmenopausia , Ensayos Clínicos Controlados Aleatorios como Asunto , Vitamina K/farmacología
16.
World J Gastroenterol ; 14(41): 6413-7, 2008 Nov 07.
Artículo en Inglés | MEDLINE | ID: mdl-19009662

RESUMEN

The prevalence of diverticular diseases of the colon, including severe and persistent bleeding in Eastern countries, has increased in the last decades. The bleeding from colonic diverticula is the most common cause of acute lower gastrointestinal bleeding. Herein, we report four cases of severe and persistent bleeding of colonic diverticular disease that could be treated with a high concentration barium enema. These four cases showed a similar pattern of bleeding whose source could not be identified. Colonoscopy revealed fresh blood in the entire colon and many diverticula were noted throughout the colon. No active bleeding source was identified, but large adherent clots in some diverticula were noted. After endoscopic and angiographic therapies failed, therapeutic barium enema stopped the severe bleeding. These patients remained free of re-bleeding in the follow-up period (range 17-35 mo) after the therapy. We report the four case series of therapeutic barium enema and reviewed the literature pertinent to this procedure.


Asunto(s)
Sulfato de Bario/administración & dosificación , Divertículo del Colon/complicaciones , Enema , Hemorragia Gastrointestinal/terapia , Técnicas Hemostáticas , Administración Rectal , Anciano , Angiografía , Colonoscopía , Divertículo del Colon/patología , Divertículo del Colon/terapia , Hemorragia Gastrointestinal/etiología , Hemorragia Gastrointestinal/patología , Humanos , Masculino , Persona de Mediana Edad , Índice de Severidad de la Enfermedad , Resultado del Tratamiento
17.
J Surg Res ; 150(1): 78-84, 2008 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-18561951

RESUMEN

BACKGROUND: Daikencyuto (DKT) is a traditional Japanese medicine (Kampo) and is a mixture of extract powders from dried Japanese pepper, processed ginger, ginseng radix, and maltose powder and has been used as the treatment of paralytic ileus. DKT may increase gastrointestinal motility by an up-regulation of the calcitonin gene-related peptide (CGRP). CGRP is also the most powerful vasoactive substance. In the present study, we investigated whether DKT has any effect on the colonic blood flow in rats. MATERIALS AND METHODS: Experiments were performed on fasted anesthetized and artificially ventilated Wistar rats. Systemic mean arterial blood pressure and heart rate were recorded. Red blood cell flux in colonic blood flow was measured using noncontact laser tissue blood flowmetry, and colonic vascular conductance (CVC) was calculated as the ratio of flux to mean arterial blood pressure. We examined four key physiological mechanisms underlying the response using blocker drugs: CGRP1 receptor blocker (CGRP(8-37)), nitric oxide synthase inhibitor, vasoactive intestinal polypeptide (VIP) receptor blocker ([4-Cl-DPhe6, Leu17]-VIP), and substance P receptor blocker (spantide). Reverse transcription-polymerase chain reaction was used for the detection of mRNA of calcitonin receptor-like receptor, receptor-activity modifying protein 1, the component of CGRP 1 receptor and CGRP. After laparotomy, a cannula was inserted into the proximal colon to administer the DKT and to measure CVC at the distal colon. RESULTS: Intracolonal administration of DKT (10, 100, and 300 mg/kg) increased CVC (basal CVC, 0.10 mL/mmHg) from the first 15-min observation period (0.14, 0.17, and 0.17 mL/mmHg, respectively) and with peak response at either 45 min (0.17 mL/mmHg by 10 mg/kg), or 75 and 60 min (0.23 and 0.21 mL/mmHg by 100 and 300 mg/kg, respectively). CGRP(8-37) completely abolished the DKT-induced hyperemia, whereas nitric oxide synthase inhibitor partially attenuated the DKT-induced hyperemia. [4-Cl-DPhe6, Leu17]-VIP and spantide did not affect the hyperemia. Japanese pepper significantly increased CVC at 45 min or later, whereas ginseng radix only showed a significant increase at 15 min. Reverse transcription-polymerase chain reaction showed that mRNA for calcitonin receptor-like receptor, receptor-activity modifying protein 1, and CGRP were expressed in rat colon and up-regulated by DKT. CONCLUSIONS: The present study demonstrated that DKT increased CVC, which was mainly mediated by CGRP and its receptor components.


Asunto(s)
Colon/irrigación sanguínea , Hiperemia/inducido químicamente , Extractos Vegetales/farmacología , Animales , Péptido Relacionado con Gen de Calcitonina/metabolismo , Proteína Similar al Receptor de Calcitonina , Medicamentos Herbarios Chinos/química , Medicamentos Herbarios Chinos/farmacología , Péptidos y Proteínas de Señalización Intracelular/metabolismo , Masculino , Medicina Kampo , Proteínas de la Membrana/metabolismo , Panax , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Ratas Wistar , Proteínas Modificadoras de la Actividad de Receptores , Receptores de Calcitonina/metabolismo , Flujo Sanguíneo Regional/efectos de los fármacos , Zanthoxylum , Zingiberaceae
18.
Yonsei Med J ; 49(1): 119-28, 2008 Feb 29.
Artículo en Inglés | MEDLINE | ID: mdl-18306478

RESUMEN

PURPOSE: To compare the effects of alendronate and raloxifene on lumbar bone mineral density (BMD), bone turnover, and lipid metabolism in elderly women with osteoporosis. SUBJECTS AND METHODS: One hundred twenty-two postmenopausal women with osteoporosis (mean age: 69.4 years) were randomly divided into 2 groups of 61 patients: the alendronate group and the raloxifene group. BMD of the lumbar spine, urinary level of cross-linked N-terminal telopeptides of type I collagen (NTX), and serum levels of alkaline phosphatase (ALP), total cholesterol (TC), high and low density lipoprotein cholesterols (LDL-C and HDL-C, respectively), and triglycerides (TG) were measured during the 12-month-treatment period. RESULTS: The trial in 50 patients in the alendronate group and 52 patients in the raloxifene group could be completed. Both alendronate and raloxifene increased lumbar BMD (+8.0% and +2.4% at 12 months, respectively), followed by reductions of urinary NTX level and serum ALP level; however, the effects of alendronate were more pronounced than those of raloxifene. Only raloxifene reduced the serum levels of TC and LDL-C (-3.9% and -7.7% at 12 months, respectively), without any significant effect on the serum HDL-C and TG levels. CONCLUSION: The present study confirmed the efficacy of alendronate greater than raloxifene in increasing lumbar BMD through its effect on marked reduction of the bone turnover more than by raloxifene, and some beneficial effects of raloxifene on lipid metabolism in elderly women with osteoporosis.


Asunto(s)
Alendronato/uso terapéutico , Densidad Ósea/efectos de los fármacos , Metabolismo de los Lípidos/efectos de los fármacos , Osteoporosis/tratamiento farmacológico , Osteoporosis/metabolismo , Clorhidrato de Raloxifeno/uso terapéutico , Anciano , Alendronato/efectos adversos , Alendronato/farmacología , Biomarcadores/sangre , Calcio/sangre , Femenino , Fracturas Óseas/prevención & control , Humanos , Fósforo/sangre , Clorhidrato de Raloxifeno/efectos adversos , Clorhidrato de Raloxifeno/farmacología , Columna Vertebral/efectos de los fármacos
19.
J Nutr Sci Vitaminol (Tokyo) ; 53(3): 191-7, 2007 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-17874822

RESUMEN

The beneficial effects of alfacalcidol (ALF) on bone mass, bone formation, and bone resorption have been established in ovariectomized rats. Our previous studies showed that high-dose glucocorticoid (GC) administration (methylprednisolone sodium succinate, 5.0 mg/kg, s.c., 3 times a week) for 4 wk induced cancellous osteopenia without significantly affecting cortical bone mass in Sprague-Dawley rats, and that high-dose GC administration for 8 wk also resulted in cortical osteopenia. The purpose of the present study was to examine the effects of ALF on cancellous and cortical bone mass in GC-treated rats. Forty female Sprague-Dawley rats, 3 mo of age, were randomized by the stratified weight method into four groups of 10 rats each, as follows: age-matched control group (CON); 8-wk GC administration with administration of vehicle during the latter 4 wk of treatment (GC group); 8-wk GC administration with administration of a low dose of ALF (0.08 Ag/kg) during the latter 4 wk of treatment (low-dose ALF group); 8-wk administration of GC with administration of a high dose ofALF (0.16 microg/kg) during the latter 4 wk of treatment (high-dose ALF group). The GC (methylprednisolone sodium succinate, 5.0 mg/kg) was administered subcutaneously 3 times a week, and ALF was administered orally 5 times a week. At the end of the experiment, static and dynamic bone histomorphometric analyses were performed on cancellous bone of the proximal tibial metaphysis and cortical bone of the tibial diaphysis. Eight-week GC administration resulted in loss of the cancellous bone volume/total tissue volume (BV/TV) and percent cortical area (Ct Ar) as a result of decreased trabecular bone formation, increased trabecular and endocortical bone resorption, and decreased periosteal bone formation. Low-dose ALF restored the cancellous BV/TV by mildly suppressing bone resorption and restoring bone formation, whereas high-dose ALF increased it beyond the value observed in the age-matched controls by strongly suppressing bone resorption and markedly increasing bone formation. Both low- and high-dose ALF prevented the GC-induced reduction of the percent Ct Ar by increasing periosteal bone formation and suppressing endocortical bone resorption. The effects of ALF on cancellous bone mass, bone formation, and bone resorption were all dose-dependent. The present study showed the beneficial effects of ALF on cancellous and cortical bone mass in GC-treated rats.


Asunto(s)
Conservadores de la Densidad Ósea/farmacología , Densidad Ósea/efectos de los fármacos , Hidroxicolecalciferoles/farmacología , Osteoporosis/prevención & control , Análisis de Varianza , Animales , Peso Corporal/efectos de los fármacos , Resorción Ósea/prevención & control , Calcio/sangre , Creatinina/sangre , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Femenino , Fémur/efectos de los fármacos , Glucocorticoides , Hemisuccinato de Metilprednisolona/administración & dosificación , Osteoporosis/inducido químicamente , Osteoporosis/patología , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Tibia/efectos de los fármacos
20.
Eur Neurol ; 56(3): 155-61, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-17035703

RESUMEN

Little is known about bone and calcium metabolism and fracture incidence in spinocerebellar degeneration (SCD) despite frequent falls and immobilization. To address bone and calcium metabolism and fracture incidence in SCD, we conducted a 10-year prospective study in a cohort of adult patients with SCD. Bone mineral density (BMD) and serum levels of ionized calcium, parathyroid hormone, 25-hydroxyvitamin D, and pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen (ICTP) were followed in 110 patients with SCD for 10 years. Age-matched healthy volunteers (n = 110) served as controls. At baseline, the SCD patients had a low BMD with high levels of serum ionized calcium and ICTP which correlated with the degree of immobilization (Barthel index). Over 10 years, serum 25-hydroxyvitamin D decreased to the osteomalacic level (<5 ng/ml), and calcium and ICTP further increased in accordance with a decreased Barthel index score. The BMD decreased by 15.2% in men and by 24.6% in women. The incidence of fractures in the patients was significantly higher as compared with the control group (men 8/49 vs. 1/42, p = 0.0428; women 16/49 vs. 2/48, p = 0.0026). Over 10 years, the BMD was significantly reduced in the SCD patients, particularly in women, which increased the risk of a fracture. Vitamin D deficiency due to sunlight deprivation, increased bone resorption due to immobilization, and frequent falls are probable causes of osteoporosis and fractures in these patients. Hypovitaminosis D and increased bone resorption may be corrected readily by the routine use of vitamin D supplements together with bisphosphonate.


Asunto(s)
Huesos/metabolismo , Calcio/metabolismo , Fracturas Óseas/epidemiología , Degeneraciones Espinocerebelosas/complicaciones , Anciano , Densidad Ósea , Desarrollo Óseo , Calcitriol/sangre , Calcio/sangre , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Atrofia de Múltiples Sistemas/sangre , Atrofia de Múltiples Sistemas/complicaciones , Hormona Paratiroidea/sangre , Degeneraciones Espinocerebelosas/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA